Provided by Tiger Trade Technology Pte. Ltd.

Anteris Technologies Global (NASDAQ Uplisting/Dual Listing)

8.45
-0.1600-1.86%
Post-market: 8.450.00000.00%16:20 EDT
Volume:568.64K
Turnover:4.83M
Market Cap:818.38M
PE:-4.33
High:8.63
Open:8.48
Low:8.41
Close:8.61
52wk High:11.06
52wk Low:3.30
Shares:96.85M
Float Shares:77.97M
Volume Ratio:1.00
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9500
EPS(LYR):-2.5505
ROE:-74.65%
ROA:-42.51%
PB:3.26
PE(LYR):-3.31

Loading ...

We Think Anteris Technologies Global (ASX:AVR) Can Afford To Drive Business Growth

Simply Wall St.
·
May 15

Anteris appoints Susan Knight, Stephen Denaro to board

Reuters
·
May 13

Anteris Appoints Susan Knight and Stephen Denaro to Its Board of Directors

THOMSON REUTERS
·
May 13

Press Release: Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors

Dow Jones
·
May 13

Anteris Technologies Global Corp-Board Appointments

THOMSON REUTERS
·
May 13

Board Appointments-AVR.O

Reuters
·
May 13

Anteris Technologies Global Corp reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Anteris Announces Results for the First Quarter of 2026

THOMSON REUTERS
·
May 13

Anteris Technologies Glb Q1 EPS $(0.28) Misses $(0.27) Estimate, Sales $494.000K Miss $766.667K Estimate

Benzinga Earnings
·
May 13

Anteris Q1 FY26 loss widens 4% to $22.9 million; net sales fall 11% to $494,000

Reuters
·
May 13

Anteris Technologies Global Corp expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
May 08

BRIEF-Anteris Technologies Announces First U.S. Patients Treated In Global Pivotal Paradigm Trial

Reuters
·
May 05

Anteris enrolls first US patients in DurAVR PARADIGM pivotal trial

Reuters
·
May 05

Statement of CDIs on issue - AVR-AVR.O

Reuters
·
May 05

Analysts Offer Insights on Healthcare Companies: Anteris Technologies Global Corp. (AVR) and Siemens Healthineers AG (OtherSEMHF)

TIPRANKS
·
May 04

Anteris Technologies Global Corp-Termination of a Material Definitive Agreement

THOMSON REUTERS
·
Apr 30

Termination of a Material Definitive Agreement-AVR.O

Reuters
·
Apr 30

Anteris Technologies Global Corp - to Discontinue Development Contributions Under Agreement With V2vmedtech - SEC Filing

THOMSON REUTERS
·
Apr 30

Notification of cessation of securities - AVR-AVR.O

Reuters
·
Apr 29

Anteris secures CMS Medicare reimbursement eligibility for PARADIGM trial under TAVR policy

Reuters
·
Apr 28